Who Owns Piramal Consumer Healthcare?

• Parent Company: Piramal Pharma Limited
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: NSE: PPLPHARMA

• Founded: 2010
• Founders: Piramal Pharma (internal development)

• Founded: 1988
• Headquarters: Mumbai, India
• Company Type: Publicly Traded
• Stock: NSE: PPLPHARMA
• Revenue: approximately INR 82 billion (FY2024)
• Employees: Approximately 10,000

Visit Piramal Pharma Limited website

• Headquarters: Mumbai, India
• Manufacturing / Operations: India

Piramal Consumer Healthcare operates within Piramal Pharma Limited's comprehensive sustainability framework, which is built on four strategic pillars covering business resilience, quality excellence, responsible operations, and stakeholder centricity. The company has established 50+ time-bound sustainability targets driving measurable impact across its operations and value chain.

S&P Global Sustainability Assessment Recognition: In 2025, Piramal Pharma Limited achieved a notable score increase on the S&P Global Corporate Sustainability Assessment (CSA), one of the world's most respected sustainability benchmarking frameworks. This recognition demonstrates the company's progress in implementing sustainable business practices across all divisions, including Piramal Consumer Healthcare.

Four-Pillar Sustainability Strategy: The company's sustainability strategy encompasses business resilience, quality and excellence, responsible operations, and stakeholder centricity. These pillars guide Piramal Consumer Healthcare's approach to environmental stewardship, product quality, operational responsibility, and community engagement across the Indian consumer healthcare market.

Quality and Excellence Commitment: Piramal Consumer Healthcare maintains rigorous quality standards across its product portfolio, which includes established brands like Littles, Lacto Calamine, i-pill, and Tetmosol. The company's quality management systems ensure product safety, efficacy, and compliance with regulatory requirements while minimizing environmental impact through efficient manufacturing processes.

Responsible Operations Framework: The company implements responsible manufacturing practices focused on resource efficiency, waste reduction, and environmental compliance. Piramal Consumer Healthcare's operations in India adhere to strict environmental standards and work to minimize the ecological footprint of consumer healthcare product manufacturing and distribution.

Stakeholder Centricity Approach: Piramal Consumer Healthcare prioritizes stakeholder engagement through its customer-centric business model. The company reaches 70 million consumers per month and focuses on building trusted relationships through transparent communication, ethical marketing practices, and community investment programs that support health and wellness initiatives.

Corporate Social Responsibility Initiatives: Through the Piramal Foundation, the company executes comprehensive CSR programs focused on healthcare access, education, and community development. These initiatives align with Piramal Consumer Healthcare's mission to provide affordable, quality healthcare solutions while contributing to social welfare and sustainable community development.

Environmental Stewardship Goals: The company has established specific environmental targets including energy efficiency improvements, water conservation measures, and waste reduction programs. Piramal Consumer Healthcare works to integrate environmental considerations into product development, packaging design, and supply chain management to minimize ecological impact.

Piramal Consumer Healthcare has received significant recognition for its rapid growth, market leadership, and brand building achievements in the Indian consumer healthcare sector. The company's performance has been acknowledged through industry rankings, business awards, and market position achievements.

Market Leadership Recognition: Piramal Consumer Healthcare is currently ranked 5th in the Indian OTC (over-the-counter) segment, representing a significant achievement for a relatively young consumer healthcare division. This ranking reflects the company's successful strategy of building power brands through strategic investments and consumer-focused product development.

Brand Portfolio Excellence: The company's portfolio includes multiple market-leading brands, with most of its products ranked either No. 1 or No. 2 in their respective markets and product categories. Brands like Littles, Lacto Calamine, i-pill, and Tetmosol have established dominant positions in their segments, demonstrating the company's ability to build and maintain successful consumer healthcare brands.

Consumer Reach Achievement: Piramal Consumer Healthcare reaches approximately 70 million consumers per month across India, representing one of the largest consumer footprints in the Indian OTC healthcare market. This extensive reach has been recognized as evidence of successful brand building and effective distribution strategies.

Business Growth Recognition: The division has been acknowledged as one of the fastest-growing businesses within Piramal Pharma Limited, demonstrating successful execution of its consumer healthcare strategy. Industry analysts have cited Piramal Consumer Healthcare's growth trajectory as evidence of effective market positioning and product innovation.

Product Innovation Awards: The company has received recognition for product innovation, particularly in categories like women's health (i-pill), skincare (Lacto Calamine), and baby care (Littles). These innovations have been acknowledged for addressing unmet consumer needs and introducing differentiated products in competitive markets.

Marketing and Communication Excellence: Piramal Consumer Healthcare's marketing strategies and consumer communication approaches have been recognized for their effectiveness in building brand awareness and driving consumer engagement. The company's customer-centric approach has been cited as a best practice in Indian consumer healthcare marketing.

Strategic Partnership Recognition: The company's selection of OMD India for its integrated media mandate in 2026 was recognized as a strategic move to enhance brand presence and consumer engagement. This partnership demonstrated industry confidence in Piramal Consumer Healthcare's growth potential and market strategy.

Piramal Consumer Healthcare has not experienced any major product recalls, but its parent company Piramal Pharma Limited has faced regulatory scrutiny and quality control issues at manufacturing facilities that have impacted the company's reputation and operations.

FDA Form 483 Regulatory Action: In February 2025, the U.S. FDA issued a Form 483 to Piramal Pharma's production facility in Maharashtra, India, detailing six observations related to quality control deficiencies. The inspection, conducted from February 11-17, 2025, identified significant shortcomings in the company's quality management systems and operational procedures.

Quality Control System Deficiencies: The FDA found that Piramal's quality control unit procedures were "not in writing and fully followed," raising concerns about the company's ability to maintain consistent quality standards across its manufacturing operations. This deficiency particularly impacts consumer healthcare products that require strict quality assurance.

Equipment Maintenance Issues: FDA inspectors discovered a leak from manufacturing equipment that resulted in "liquid being present throughout the floor" in a facility room. More concerning, no operator or supervisor was present during the incident, and there was "no documentation of the operator activity or his presence within the room," indicating serious gaps in operational oversight.

Manufacturing Deviation Investigation Failures: The FDA noted that Piramal's investigations into active pharmaceutical ingredient (API) batch deviations lacked adequate follow-up. While four manufacturing deviations were reported in March 2024, the company failed to produce a documented quality risk assessment to determine the feasibility of continuing API batch production.

Previous Regulatory Issues: This 2025 FDA action followed a similar Form 483 issued in February 2024 at Piramal's manufacturing plant in Michigan, USA, indicating a pattern of quality control challenges across the company's global manufacturing network. The repeated regulatory scrutiny raises concerns about systemic quality management issues.

Impact on Consumer Healthcare Division: While the FDA actions primarily targeted Piramal Pharma's API manufacturing operations, the regulatory scrutiny affects the entire company's reputation and could impact consumer confidence in Piramal Consumer Healthcare products. The quality control deficiencies raise questions about the company's ability to maintain consistent product safety and efficacy standards.

Operational Oversight Challenges: The incidents revealed significant gaps in operational supervision and documentation, particularly regarding employee presence monitoring and equipment maintenance procedures. These shortcomings suggest broader issues with manufacturing discipline and quality assurance protocols that could affect consumer product manufacturing.